On November 17, PEGBIO CO-B fell 5.43% in Regular Trading, trading at HK$3.065, with turnover of HK$36.65 million.
The latest market-moving catalyst was a pullback after the stock had strengthened on news that its core product Paidakang was added to the 2026 National Reimbursement Drug List, a development previously seen as a major commercialization milestone.
Background disclosures said Paidakang, or visepegenatide injection, is the company’s first approved innovative drug product for blood glucose control in adults with type 2 diabetes. The company had earlier entered an exclusive mainland China commercialization partnership with Shanghai Tengrui Pharmaceutical and set a cumulative sales target of more than RMB10 billion. Management said NRDL inclusion should improve affordability, broaden hospital access, and support nationwide clinical promotion and market coverage.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments